Company press releases
| Released | Company | Title | Industry | Topic |
|---|---|---|---|---|
| 10 Sep 2021 17:06 CEST |
VACCIBODY | Vaccibody AS - Mandatory notification of intra group transfer of shares by primary insider’s related party | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 07 Sep 2021 18:04 CEST |
VACCIBODY | Share capital increase from exercise of warrants | 20103010 Biotechnology | Total number of voting rights and capital |
| 26 Aug 2021 06:30 CEST |
VACCIBODY | Vaccibody AS - Quarterly report Q2 2021 | 20103010 Biotechnology | Half yearly financial reports and audit reports/limited reviews |
| 23 Aug 2021 08:30 CEST |
VACCIBODY | Vaccibody Q2 and half-year report 2021 webcast | 20103010 Biotechnology | Non-regulatory press releases |
| 12 Jul 2021 06:45 CEST |
VACCIBODY | Vaccibody enters into worldwide license agreement with Adaptive Biotechnologies for clinically validated SARS-CoV-2 T cell epitopes to combine in a second-generation T cell vaccine candidate to specifically address emerging SARS-CoV-2 variants of concern | 20103010 Biotechnology | Non-regulatory press releases |
| 29 Jun 2021 18:43 CEST |
VACCIBODY | Share capital increase from exercise of warrants | 20103010 Biotechnology | Total number of voting rights and capital |
| 29 Jun 2021 06:45 CEST |
VACCIBODY | Vaccibody to initiate a phase 1/2 trial to evaluate two second-generation SARS CoV-2 virus DNA vaccine candidates to address emerging variants of concern | 20103010 Biotechnology | Non-regulatory press releases |
| 14 Jun 2021 23:40 CEST |
VACCIBODY | Grant of Share Options | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 10 Jun 2021 00:16 CEST |
VACCIBODY | Vaccibody to present at Goldman Sachs 42nd Annual Global Healthcare Conference | 20103010 Biotechnology | Non-regulatory press releases |
| 03 Jun 2021 22:50 CEST |
VACCIBODY | Grant of Restricted Share Units and Share Options | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 31 May 2021 17:06 CEST |
VACCIBODY | Vaccibody to present at Jefferies Virtual Healthcare Conference (June 1-4, 2021) | 20103010 Biotechnology | Non-regulatory press releases |
| 12 May 2021 18:15 CEST |
VACCIBODY | Share capital increase from exercise of warrants | 20103010 Biotechnology | Total number of voting rights and capital |
| 12 May 2021 08:30 CEST |
VACCIBODY | Vaccibody AS - Quarterly report Q1 2021 | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 12 May 2021 08:29 CEST |
VACCIBODY | Vaccibody appoints Mikkel Wandahl Pedersen as new Chief Scientific Officer and Agnete B. Fredriksen as Chief Innovation & Strategy Officer | 20103010 Biotechnology | Non-regulatory press releases |
| 07 May 2021 18:43 CEST |
VACCIBODY | Mandatory notification of exercise of warrants | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 05 May 2021 14:28 CEST |
VACCIBODY | Vaccibody AS appoints Dr. Volck, M.D., Ph.D. as new member of the Board | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 05 May 2021 14:15 CEST |
VACCIBODY | Minutes of the Annual General Meeting | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 04 May 2021 20:42 CEST |
VACCIBODY | Grant of share options | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 30 Apr 2021 08:00 CEST |
VACCIBODY | Status update on VB C-02 clinical trial with VB10.16 and immune checkpoint inhibitor atezolizumab in patients with advanced cervical cancer | 20103010 Biotechnology | Non-regulatory press releases |